b'olaparib is the first cancer drug to target inherited genetic mutations .'
b'up to 30 per cent of men with advanced prostate cancer have tumours with genetic defects - and they responded well to olaparib .'
b'drug prolongs time a sufferer can live without disease getting worse .'